David Bonita Net Worth

The estimated Net Worth of David P Bonita is at least $141 Million dollars as of 22 May 2023. David Bonita owns over 869,565 units of Tricida Inc stock worth over $1,113,173 and over the last 8 years he sold TCDA stock worth over $139,123,127. In addition, he makes $294,000 as Independent Director at Tricida Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Bonita TCDA stock SEC Form 4 insiders trading

David has made over 24 trades of the Tricida Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 869,565 units of TCDA stock worth $4,999,999 on 22 May 2023.

The largest trade he's ever made was selling 10,280,947 units of Tricida Inc stock on 22 November 2022 worth over $2,158,999. On average, David trades about 466,082 units every 52 days since 2016. As of 22 May 2023 he still owns at least 10,119,756 units of Tricida Inc stock.

You can see the complete history of David Bonita stock trades at the bottom of the page.

David Bonita biography

Dr. David P. Bonita M.D. serves as Independent Director of the Company. Dr. Bonita has been a member of OrbiMed Advisors LLC, an investment firm and an affiliate of one of our principal stockholders, since June 2013. Dr. Bonita has served on the board of directors of IMARA Inc. since March 2019. Dr. Bonita also previously served on the boards of directors of Ambit Biosciences Corporation, Clementia Pharmaceuticals, Loxo Oncology, Inc., SI-BONE Inc., and ViewRay Inc. Dr. Bonita currently serves on the boards of directors of the following private companies: Acutus Medical Inc., Bolt Medical, Inc., Ikena Oncology, Inc., Prelude Therapeutics Inc., Repare Therapeutics Inc., and Sublimity Therapeutics, Inc.; and has previously served on the boards of directors of Arrys Therapeutics Inc., CardiAQ Valve Technologies, Inc., Cryterion Medical Inc., Enobia Pharma Inc., and Keystone Heart Ltd. Dr. Bonita has also worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peer-reviewed journals based on signal transduction research performed at the Harvard Medical School. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University.

What is the salary of David Bonita?

As the Independent Director of Tricida Inc, the total compensation of David Bonita at Tricida Inc is $294,000. There are 10 executives at Tricida Inc getting paid more, with Gerrit Klaerner having the highest compensation of $10,168,700.

How old is David Bonita?

David Bonita is 44, he's been the Independent Director of Tricida Inc since 2014. There are 14 older and 2 younger executives at Tricida Inc. The oldest executive at Tricida Inc is Robert Alpern, 69, who is the Independent Director.

What's David Bonita's mailing address?

David's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.

Insiders trading at Tricida Inc

Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., and Healthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.

What does Tricida Inc do?

Complete history of David Bonita stock trades at ViewRay, Tricida Inc, SI-BONE Inc, Imara Inc, Repare Therapeutics, Acutus Medical, and Prelude Therapeutics Inc

Tricida Inc executives and stock owners

Tricida Inc executives and other stock owners filed with the SEC include:

• Gerrit Klaerner,
  President, Chief Executive Officer, Director
• Dawn Parsell,
  Executive Vice President - Clinical Development
• Geoffrey Parker,
  Chief Financial Officer, Executive Vice President
• Edward Hejlek,
  Senior Vice President
• Dr. Gerrit Klaerner Ph.D.,
  Founder, Pres, CEO & Exec. Director
• Dr. Dawn Parsell Ph.D.,
  Exec. VP of Clinical Devel.
• Geoffrey M. Parker,
  COO, CFO & Exec. VP
• Robert L. McKague J.D.,
  Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
• Dr. Wilhelm Stahl,
  Exec. VP & CTO
• Klaus Veitinger,
  Independent Chairman of the Board
• David Bonita,
  Independent Director
• Kathryn Falberg,
  Independent Director
• David Hirsch,
  Independent Director
• Sandra Coufal,
  Independent Director
• Robert Alpern,
  Independent Director
• Marc Cobo,
  Senior Vice President - Finance, Chief Accounting Officer
• Robert McKague,
  Executive Vice President, General Counsel, Secretary
• Edward J. Hejlek Esq., J.D.,
  Exec. VP of Intellectual Property
• Jackie Cossmon,
  VP of Investor Relations & Communications
• Annie Yoshiyama,
  VP of Fin. & Chief Accounting Officer
• Claire Lockey,
  Chief Dev. Officer and Sr. VP
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Ven...,
  
• Beek Jeroen B Van,
  Chief Comm Officer and Sr VP
• Steffen Pietzke,
  VP Fin & Chief Acct Officer
• Capital Partners Ii, Llc Lo...,
  
• Advisors Llc Orbi Med Capit...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Wilhelm Stahl,
  EVP, Chief Tech Officer
• Brian M.Sibling Capital Ven...,
  
• Susannah Cantrell,
  EVP, Chief Comm. Officer
• Brian M.Sibling Capital Fun...,
  
• Brian M.Sibling Capital Fun...,
  
• Annie Yoshiyama,
  Senior VP, Finance and CAO
• Healthcare Capital Partners...,